Severe Mucositis Secondary to Pembrolizumab: Reports of Two Cases, Review of the Literature, and an Algorithm for Management.

The indications for use of programed cell death receptor (PD-1) inhibitors to treat cancer continues to expand rapidly. Treatment with PD-1 inhibitors has been associated with numerous immune-mediated mucocutaneous side effects. Here, we report 2 cases of severe mucositis caused by the PD-1 inhibitor pembrolizumab and review the defining features of similar cases.

A Retrospective Study of a Multi-Center Case Series of 452 Zygomatic Implants Placed Over 5 Years for Treatment of Severe Maxillary Atrophy.

Background: Treatment of the severely resorbed maxilla traditionally has been managed with such protocols as sinus elevation, bone and soft-tissue grafting, and osteotomy procedures. The use of zygomatic implants has made it possible to circumvent such procedures, allowing immediate loading of implants with fixed prostheses.

Objective: This study reports the success rate of 452 zygomatic implants placed and restored in 249 patients over 5 years in a multi-center setting.